Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
Date:12/5/2007

DETROIT, Dec. 5 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg (Amlodipine).

Amlodipine is indicated for the treatment of hypertension, for the symptomatic treatment of chronic stable angina, and for the treatment of confirmed or suspected vasospastic angina. Amlodipine is the bioequivalent to Norvasc(R), a registered trademark of Pfizer Inc. According to IMS Data, based upon the most recent quarterly sales ended September 2007, Amlodipine generic and brand products combined have a run rate of approximately $550 million with ten generic competitors.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "This product marks our seventh final approval since June 30, 2007. We are evaluating the market place and internal production planning in an effort to monetize this approval as soon as possible. This will bring our total product selection to 43 different products represented by 92 various strengths."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Tampa, Fla (PRWEB) , ... January 17, 2017 , ... ... IT Excellence Award for Innovation of the Year. , Each year, Pink ... has taken an innovative approach to address a specific business problem or opportunity. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... visualize, detect, and eliminate cyber threats in real-time, today announced a strategic partnership ... headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader ... new agreement as part of a long-term extension of their media partnership. The partnership, ... of some of the sport’s premier events exclusively on FloWrestling.com as well as usage ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Market 2016-2020" report to their offering. ... The global artificial pancreas devices system ... 2016-2020. Global Artificial Pancreas Devices System Market 2016-2020, has ... industry experts. The report covers the market landscape and its growth ...
(Date:1/17/2017)... 17, 2017 The interventional radiology products market ... from USD 6.35 billion in 2016, at a CAGR ... of this market are rising incidence of chronic diseases, ... surgeries. The global interventional radiology products market ... On the basis of type, the stents segment is ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
Breaking Medicine Technology: